WO2007149438A3 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- WO2007149438A3 WO2007149438A3 PCT/US2007/014282 US2007014282W WO2007149438A3 WO 2007149438 A3 WO2007149438 A3 WO 2007149438A3 US 2007014282 W US2007014282 W US 2007014282W WO 2007149438 A3 WO2007149438 A3 WO 2007149438A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonist
- antagonist
- pharmaceutical compositions
- seal coat
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
Abstract
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07809672T ES2385612T3 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
MX2008016372A MX2008016372A (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions. |
CN2007800303040A CN101677963B (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
JP2009516543A JP5566102B2 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical composition |
SI200730929T SI2034975T1 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
CA2655835A CA2655835C (en) | 2006-06-19 | 2007-06-19 | Abuse-resistant pharmaceutical compositions of opioid agonists |
PL07809672T PL2034975T3 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
KR20157004494A KR20150029762A (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
AT07809672T ATE552829T1 (en) | 2006-06-19 | 2007-06-19 | PHARMACEUTICAL COMPOSITIONS |
EP07809672A EP2034975B8 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
KR1020147011462A KR20140079441A (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
BRPI0714039A BRPI0714039A8 (en) | 2006-06-19 | 2007-06-19 | PHARMACEUTICAL COMPOSITION |
AU2007261451A AU2007261451A1 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
DK07809672.4T DK2034975T3 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
NZ573757A NZ573757A (en) | 2006-06-19 | 2007-06-19 | Coated multilayer oral dosage forms of naltrexone hydrochloride |
KR1020097000449A KR101486228B1 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
IL195834A IL195834A (en) | 2006-06-19 | 2008-12-10 | Compositions comprising a plurality of multi-layer pellets and use thereof |
ZA2008/10501A ZA200810501B (en) | 2006-06-19 | 2008-12-11 | Pharmaceutical compositions |
IL235150A IL235150A (en) | 2006-06-19 | 2014-10-19 | Pharmaceutical compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81494906P | 2006-06-19 | 2006-06-19 | |
US60/814,949 | 2006-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007149438A2 WO2007149438A2 (en) | 2007-12-27 |
WO2007149438A3 true WO2007149438A3 (en) | 2009-09-24 |
Family
ID=38834070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014282 WO2007149438A2 (en) | 2006-06-19 | 2007-06-19 | Pharmaceutical compositions |
Country Status (23)
Country | Link |
---|---|
US (9) | US8158156B2 (en) |
EP (4) | EP2484346B1 (en) |
JP (1) | JP5566102B2 (en) |
KR (3) | KR101486228B1 (en) |
CN (1) | CN101677963B (en) |
AT (1) | ATE552829T1 (en) |
AU (4) | AU2007261451A1 (en) |
BR (1) | BRPI0714039A8 (en) |
CA (1) | CA2655835C (en) |
CY (4) | CY1112868T1 (en) |
DK (4) | DK2526932T3 (en) |
ES (4) | ES2622576T3 (en) |
HK (1) | HK1173980A1 (en) |
HU (3) | HUE033058T2 (en) |
IL (2) | IL195834A (en) |
MX (1) | MX2008016372A (en) |
NZ (1) | NZ573757A (en) |
PL (4) | PL2526932T3 (en) |
PT (4) | PT2526932T (en) |
RU (1) | RU2445077C2 (en) |
SI (4) | SI2484346T1 (en) |
WO (1) | WO2007149438A2 (en) |
ZA (1) | ZA200810501B (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003522144A (en) * | 2000-02-08 | 2003-07-22 | ユーロ−セルティーク,エス.エイ. | Controlled release compositions comprising opioid agonists and antagonists |
US20030004177A1 (en) * | 2001-05-11 | 2003-01-02 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
PT1551372T (en) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and metohds |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
RU2350327C2 (en) | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Compounds causing weight loss |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
BRPI0618918B8 (en) * | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | use of a first compound and a second compound to treat a blood glucose condition |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
EP1810678A1 (en) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
PL2526932T3 (en) | 2006-06-19 | 2017-12-29 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
JP2010506833A (en) * | 2006-10-11 | 2010-03-04 | アルファーマ,インコーポレイテッド | Pharmaceutical composition |
RU2009116834A (en) * | 2006-11-09 | 2010-12-20 | Ориксиджен Терапьютикс, Инкорпорэйтд Сша/Сша (Us) | METHOD FOR ADMINISTRATION OF MEDICINES FOR REDUCING WEIGHT |
WO2009032270A2 (en) * | 2007-09-04 | 2009-03-12 | Alpharma, Inc. | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
AU2014250614B2 (en) * | 2007-09-04 | 2016-11-10 | Alpharma Pharmaceuticals, Llc | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
AU2014216032B2 (en) * | 2007-12-17 | 2016-11-03 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
EP2224805A4 (en) * | 2007-12-17 | 2013-10-16 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
AU2008346870A1 (en) * | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AU2015200313B2 (en) * | 2007-12-17 | 2016-12-01 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
CA2709950A1 (en) * | 2007-12-17 | 2009-07-09 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AU2008338439A1 (en) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals. Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CA2723307C (en) * | 2008-05-05 | 2017-08-22 | Euro-Celtique S.A. | Tamper resistant opioid composition for treating skin lesions |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Methods for treating visceral fat conditions |
CN102164589A (en) * | 2008-09-24 | 2011-08-24 | 赢创罗姆有限公司 | PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
FR2936709B1 (en) | 2008-10-02 | 2012-05-11 | Ethypharm Sa | ALCOHOL-RESISTANT TABLETS. |
WO2010151741A1 (en) * | 2009-06-25 | 2010-12-29 | Elite Laboratories, Inc. | Abuse resistant oral dosage forms |
ES2762113T3 (en) * | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Methods of providing weight loss therapy in patients with major depression |
ES2592277T3 (en) * | 2010-04-02 | 2016-11-29 | Buzzz Pharmaceuticals Limited | Transdermal deterrent formulations of abuse of opioid agonists and agonists |
FR2959935B1 (en) * | 2010-05-14 | 2013-02-08 | Ethypharm Sa | ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM |
RS65198B1 (en) * | 2010-12-03 | 2024-03-29 | Nalpropion Pharmaceuticals Llc | Increasing drug bioavailability in naltrexone therapy |
CA2822769C (en) * | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
US20120164207A1 (en) * | 2010-12-23 | 2012-06-28 | Gooberman Lance L | Degradable networks for sustained release and controlled release depot drug delivery applications |
KR20160031038A (en) | 2011-02-02 | 2016-03-21 | 알파마 파머슈티컬스 엘엘씨 | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
EP2736495B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
DK2736497T3 (en) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Shock-resistant tablet that provides an immediate release of a drug. |
WO2013038268A1 (en) * | 2011-09-16 | 2013-03-21 | Purdue Pharma L.P. | Tamper resistant immediate release formulations |
WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
EP2872121B1 (en) | 2012-07-12 | 2018-09-05 | SpecGx LLC | Extended release, abuse deterrent pharmaceutical compositions |
US11571390B2 (en) * | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
JP2016535778A (en) | 2013-10-31 | 2016-11-17 | シーマ・ラブス・インコーポレーテッド | Abuse deterrent dosage form |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
ES2750853T3 (en) * | 2014-10-14 | 2020-03-27 | Hisamitsu Pharmaceutical Co | Adhesive patch |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CA2970065A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
US9745820B2 (en) * | 2015-04-28 | 2017-08-29 | Thru Tubing Solutions, Inc. | Plugging device deployment in subterranean wells |
US10383825B2 (en) | 2015-08-13 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | Calcium alginate dosage formulations, and methods of making and using thereof |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
RU2620254C1 (en) * | 2016-01-20 | 2017-05-24 | Русан Фарма Лимитед | Implantable naltrexone tablets |
EP3210630A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
EP3210596A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical composition |
EP3231420A1 (en) | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
US20170312226A1 (en) * | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US10687192B2 (en) * | 2016-12-08 | 2020-06-16 | Parallel Wireless, Inc. | Dynamic public warning system for in-vehicle eNodeB |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
US10624856B2 (en) | 2018-01-31 | 2020-04-21 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
CN108283626B (en) * | 2018-02-06 | 2021-02-26 | 江苏长泰药业有限公司 | Film for blocking drug release and preparation thereof |
WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
CN114081934B (en) * | 2022-01-20 | 2022-04-12 | 江西省中医药研究院 | Traditional Chinese medicine composition and quality detection method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0271193A2 (en) * | 1986-10-31 | 1988-06-15 | Euroceltique S.A. | Controlled release hydromorphone composition |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US20030004177A1 (en) * | 2001-05-11 | 2003-01-02 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030124185A1 (en) * | 2001-08-06 | 2003-07-03 | Benjamin Oshlack | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20040254208A1 (en) * | 2003-04-29 | 2004-12-16 | Eckard Weber | Compositions for affecting weight loss |
WO2005055981A2 (en) * | 2003-12-09 | 2005-06-23 | Euro-Celtique S.A. | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
WO2005081825A2 (en) * | 2004-02-23 | 2005-09-09 | Euro-Celtique S.A. | Abuse resistance opioid transdermal delivery device |
WO2007145863A2 (en) * | 2006-06-05 | 2007-12-21 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
Family Cites Families (324)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
GB751767A (en) | 1953-01-21 | 1956-07-04 | Merck & Co Inc | Improvements in antitussive compositions |
GB769517A (en) | 1953-10-20 | 1957-03-06 | Merck & Co Inc | Analgesic compositions |
US2779569A (en) * | 1954-03-16 | 1957-01-29 | Golden W Gills | Sectionalized mast hoist apparatus |
GB791644A (en) | 1955-04-20 | 1958-03-05 | Nicholas Pty Ltd | Barbiturate pharmaceutical preparations |
GB808269A (en) | 1956-10-10 | 1959-01-28 | Nicholas Pty Ltd | Barbiturate pharmaceutical preparations |
US3852058A (en) | 1957-05-27 | 1974-12-03 | Monsanto Co | Herbicidal compositions and methods |
US2945049A (en) | 1959-05-25 | 1960-07-12 | Gen Mills Inc | Salts of basic amino acids and linoleic acid |
US2981641A (en) * | 1960-01-21 | 1961-04-25 | Stauffer Chemical Co | Tobacco products |
US3071509A (en) * | 1961-03-09 | 1963-01-01 | Stauffer Chemical Co | N-alkyl-nornicotine:nicotine antagonist |
US3493657A (en) * | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3860619A (en) | 1969-05-09 | 1975-01-14 | Novo Terapeutisk Labor As | Sulphonylurea derivatives |
US3689574A (en) | 1970-04-28 | 1972-09-05 | Exxon Research Engineering Co | 3,4,5-trimethylcyclohexanol |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) * | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
GB1390772A (en) | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3971725A (en) | 1972-11-06 | 1976-07-27 | Colgate-Palmolive Company | 2-Mercaptoquinoxaline-1-oxides, salts thereof and 2-(1-oxoquinoxalinyl)disulfides in detergent compositions |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3916889A (en) | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4048181A (en) | 1975-11-06 | 1977-09-13 | Colgate-Palmolive Company | Derivatives of mercaptopyridine-1-oxide |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4111201A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4366159A (en) | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
DK150008C (en) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION |
JPS59500418A (en) | 1982-03-16 | 1984-03-15 | ザ ロツクフエラ− ユニバ−シテイ | How to recover from gastrointestinal dysfunction |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4424205A (en) | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) * | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
US4803208A (en) * | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
JPS59122425U (en) | 1983-02-08 | 1984-08-17 | カルソニックカンセイ株式会社 | bearing |
US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4681897A (en) | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4783456A (en) | 1984-03-02 | 1988-11-08 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US4795327A (en) | 1984-03-26 | 1989-01-03 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
DE3434946A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | DIARYLACETYLENE, THEIR PRODUCTION AND USE |
US4573995A (en) * | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
ATE61935T1 (en) | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | PROCESS FOR PRODUCTION OF MICROCAPSULES. |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
ZA861211B (en) | 1985-02-25 | 1987-10-28 | Lilly Co Eli | Analgesic composition |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
FR2585246A1 (en) * | 1985-07-26 | 1987-01-30 | Cortial | PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE |
US4655766A (en) * | 1985-08-01 | 1987-04-07 | Alza Corporation | Fluid imbibing pump with self-regulating skin patch |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
JPS63500799A (en) | 1985-09-06 | 1988-03-24 | ベーカー・カミンス・ファーマシューティカルス・インコーポレーテッド | Methods and compositions for obtaining long-lasting opioid antagonism |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4935429A (en) | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
US4846199A (en) | 1986-03-17 | 1989-07-11 | The Regents Of The University Of California | Smoking of regenerated tobacco smoke |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP0249347B1 (en) * | 1986-06-10 | 1994-06-29 | Euroceltique S.A. | Controlled release dihydrocodeine composition |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
CH669523A5 (en) | 1986-06-25 | 1989-03-31 | Mepha Ag | |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
IN165717B (en) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
US4992464A (en) | 1987-02-10 | 1991-02-12 | Abbott Laboratories | Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4871546A (en) | 1987-06-29 | 1989-10-03 | Sandoz Pharm. Corp. | Gastrointestinal protective coating formulations |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
JP2643222B2 (en) | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | Multi-layer granules |
DE3812567A1 (en) | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) * | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4939149A (en) | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5330766A (en) | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5021053A (en) | 1989-07-14 | 1991-06-04 | Alza Corporation | Oral osmotic device with hydrogel driving member |
US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5219858A (en) | 1990-03-27 | 1993-06-15 | Parnell Pharmaceuticals, Inc. | Method and compositions for effecting withdrawal from drug dependency |
US5086058A (en) * | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
US5151093A (en) * | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HU208633B (en) * | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
US5208037A (en) | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) * | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
DE4123106A1 (en) * | 1991-07-09 | 1993-01-14 | Schering Ag | MEDICINAL PRODUCTS FOR THE TREATMENT OF WITHDRAWAL SYMPTOMS |
KR100221695B1 (en) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
CA2095523C (en) | 1991-09-06 | 2004-06-22 | Robert B. Raffa | Composition comprising a tramadol material and acetaminophen and its use |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5226331A (en) | 1991-10-03 | 1993-07-13 | General Electric Company | Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US7070806B2 (en) | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
GB9203689D0 (en) * | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
SE9201239D0 (en) | 1992-04-21 | 1992-04-21 | Kabi Pharmacia Ab | AGENTS FOR TREATING SUBSTANCE ABUSE DISORDERS |
ATE404201T1 (en) | 1992-06-22 | 2008-08-15 | Univ California | GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
EP0653935B1 (en) | 1992-08-05 | 2002-05-08 | F.H. FAULDING & CO. LIMITED | Pelletised pharmaceutical composition |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
JP3253083B2 (en) | 1992-08-20 | 2002-02-04 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Method of Obtaining Microstructured Surface of Oriented Polymer Substrate Using Laser Radiation |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
JPH08504189A (en) | 1992-09-21 | 1996-05-07 | キン、ボーイ | Identification and use of low / non-epileptic opioid analgesics |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5376384A (en) | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
US5656291A (en) | 1994-03-16 | 1997-08-12 | Pharmacia & Upjohn Aktiebolag | Controlled release preparation |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4325465B4 (en) | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Oral pharmaceutical preparation for pain therapy |
US5362496A (en) | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
EP1442745A1 (en) | 1993-10-07 | 2004-08-04 | Euro-Celtique | Orally administrable opioid formulations having extended duration of effect |
US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
US5475995A (en) | 1994-05-16 | 1995-12-19 | Livingston; George G. | Truck spare tire locking rod |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
JPH07330606A (en) * | 1994-06-08 | 1995-12-19 | Towa Yakuhin Kk | Granule for nicardipine prolonged-action preparation |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
US5529787A (en) | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US6103734A (en) | 1994-11-04 | 2000-08-15 | Legarda Ibanez; Juan Jose | Drug combination as a medicament to suppress the dependence of individuals to opiates |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
CA2206119C (en) * | 1994-12-12 | 2008-05-13 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US6156343A (en) | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
US5834024A (en) * | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
CA2195119C (en) | 1995-06-09 | 2001-09-11 | Mark Chasin | Formulations and methods for providing prolonged local anesthesia |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US5998434A (en) | 1995-12-06 | 1999-12-07 | Eli Lilly And Company | Composition for treating pain |
FR2742660B1 (en) * | 1995-12-22 | 1998-04-03 | Ethypharm Lab Prod Ethiques | NOVEL FORMS OF EXTENDED RELEASE MICROGRANULES CONTAINING DILTIAZEM AS ACTIVE INGREDIENT |
IT1282650B1 (en) | 1996-02-19 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS |
US6159501A (en) | 1996-03-08 | 2000-12-12 | Nycomed Danmark A/S | Modified release multiple-units dosage composition for release of opioid compounds |
WO1997033566A2 (en) | 1996-03-12 | 1997-09-18 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
AUPN969796A0 (en) | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
BR9706897B1 (en) | 1996-05-20 | 2010-09-21 | pharmaceutical dosage form. | |
AU724490B2 (en) | 1996-08-29 | 2000-09-21 | Jagotec Ag | Tablet with controlled release of alfuzosin hydrochloride |
JPH10130142A (en) | 1996-10-31 | 1998-05-19 | Zensei Yakuhin Kogyo Kk | Sustained release type compressed preparation |
DE19651551C2 (en) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioid antagonist-containing galenic formulation |
DE29719704U1 (en) | 1997-02-14 | 1998-01-22 | Goedecke Ag | Stable preparations of naloxone hydrochloride |
ATE186643T1 (en) | 1997-02-14 | 1999-12-15 | Goedecke Ag | STABILIZATION OF NALOXONE HYDROCHLORIDE |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19710008A1 (en) | 1997-03-12 | 1998-09-17 | Basf Ag | Solid, at least two-phase formulations of a sustained-release opioid analgesic |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
US6551616B1 (en) | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US5919473A (en) | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
US7056532B1 (en) | 1997-06-13 | 2006-06-06 | Univ. Nebraska Bd. of Regents | Compositions for delivery of biological agents and methods for the preparation thereof |
PT1009387E (en) | 1997-07-02 | 2006-08-31 | Euro Celtique Sa | STABILIZED CONTROLLED FREQUENCY FORMULATIONS OF TRAMADOL |
ATE210983T1 (en) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | STABILIZED COMBINATION MEDICINAL PRODUCT CONTAINING NALOXONE AND AN OPIATE ANALGESIC |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
JP4221068B2 (en) | 1997-12-17 | 2009-02-12 | 興和創薬株式会社 | Theophylline sustained release tablet and method for producing the same |
CN1204890C (en) | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | Method for preventing abuse of opioid dosage forms |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
RU2241458C2 (en) * | 1997-12-22 | 2004-12-10 | Эро-Селтик, С.А. | Combinations of agonist/antagonist for opioid |
KR100658489B1 (en) | 1998-11-10 | 2006-12-18 | 얀센 파마슈티카 엔.브이. | HIV replication inhibiting pyrimidines |
FR2787715B1 (en) | 1998-12-23 | 2002-05-10 | Synthelabo | PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20040258750A1 (en) | 1999-06-28 | 2004-12-23 | Gerard Alaux | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
FR2795961B1 (en) | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED FENOFIBRATE, A SURFACTANT AND A BINDING CELLULOSIC DERIVATIVE AND PREPARATION METHOD |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
KR100820605B1 (en) | 1999-09-24 | 2008-04-08 | 얀센 파마슈티카 엔.브이. | Antiviral compositions |
EP1225897B1 (en) | 1999-11-01 | 2004-09-08 | RHODES, John | Composition for treatment of constipation and irritable bowel syndrome |
WO2001037785A2 (en) | 1999-11-29 | 2001-05-31 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
JP2003522144A (en) * | 2000-02-08 | 2003-07-22 | ユーロ−セルティーク,エス.エイ. | Controlled release compositions comprising opioid agonists and antagonists |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
ATE326222T1 (en) | 2000-03-15 | 2006-06-15 | Wolfgang Sadee | NALOXONE AND NALTREXONE ANALOGUES IN DRUG ABUSE TREATMENT |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
JP2004515455A (en) | 2000-05-05 | 2004-05-27 | ペイン・セラピューティクス・インコーポレイテッド | Opioid antagonist compositions and dosage forms |
US20040024004A1 (en) * | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
WO2001093852A2 (en) | 2000-06-09 | 2001-12-13 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
DE60138771D1 (en) | 2000-10-23 | 2009-07-02 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-4H-PYRROLOA1,2-AÜ1,4Ü BENZODIAZEPINE AS FUNGICIDES SUBSTITUTED IN THE 4-POSITION |
ATE533478T1 (en) | 2001-05-01 | 2011-12-15 | Euro Celtique Sa | ABUSE-PROOF OPIOIDS WITH TRANSDERMAL SYSTEMS |
CN1525851A (en) * | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | Abuse-resistant controlled-release opioid dosage form |
EP1390866B1 (en) * | 2001-05-22 | 2010-01-20 | Euro-Celtique S.A. | Container and method for dispensing transdermal dosage forms |
WO2002094172A2 (en) | 2001-05-22 | 2002-11-28 | Euro-Celtique | Compartmentalized dosage form |
US20030064122A1 (en) | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
US7968119B2 (en) * | 2001-06-26 | 2011-06-28 | Farrell John J | Tamper-proof narcotic delivery system |
EP2311460A1 (en) | 2001-07-06 | 2011-04-20 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
SI1416842T1 (en) | 2001-07-18 | 2009-06-30 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
ES2326794T3 (en) * | 2001-08-06 | 2009-10-20 | Euro-Celtique S.A. | FORMULATIONS OF OPIOID AGONISTS WITH LIBERABLE AND SEQUESTED ANTAGONISTS. |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US20030049317A1 (en) * | 2001-08-30 | 2003-03-13 | Lindsay David R. | Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
CA2459976A1 (en) | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US7163696B2 (en) | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
EP1578350B1 (en) | 2002-03-26 | 2009-05-27 | Euro-Celtique S.A. | Sustained-release gel coated compositions |
KR20050050615A (en) | 2002-04-23 | 2005-05-31 | 알자 코포레이션 | Transdermal analgesic systems with reduced abuse potential |
AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
MXPA05001826A (en) * | 2002-08-15 | 2005-04-19 | Euro Celtique Sa | Pharmaceutical compositions. |
US20050020613A1 (en) * | 2002-09-20 | 2005-01-27 | Alpharma, Inc. | Sustained release opioid formulations and method of use |
PT1551372T (en) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and metohds |
JP5189242B2 (en) | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | Abuse-resistant pharmaceutical composition |
US20050191244A1 (en) | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
AU2003296954A1 (en) | 2002-12-13 | 2004-07-09 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
US7524515B2 (en) | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
ES2396334T3 (en) | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for PARP inhibition |
CN100588391C (en) | 2003-08-12 | 2010-02-10 | 恩德制药公司 | Single long acting slow-release tablet for deterring abuse of medicine |
US20050245557A1 (en) | 2003-10-15 | 2005-11-03 | Pain Therapeutics, Inc. | Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain |
DE10353196A1 (en) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Multilayer dosage form with a matrix influencing the delivery of a modulatory substance |
DE10353186A1 (en) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Multilayer dosage form containing a modulatory substance in relation to the release of active ingredient |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EP1541121B1 (en) | 2003-12-11 | 2007-03-21 | Rohm And Haas Company | System and process for releasing encapsulated active ingredients |
US20050142203A1 (en) | 2003-12-30 | 2005-06-30 | Grant Heinicke | Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same |
US20070196396A1 (en) | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
HUE033015T2 (en) | 2004-05-04 | 2017-11-28 | Innophos Inc | Directly compressible tricalcium phosphate |
CN101061111A (en) | 2004-09-20 | 2007-10-24 | 库多斯药物有限公司 | DNA-PK inhibitors |
US20060069263A1 (en) * | 2004-09-30 | 2006-03-30 | Irina Gribun | Process for the reduction of (S)-2-amino-6-propionamido-4,5,6,7-tetrahydrobenzo-thiazole |
US20060099259A1 (en) | 2004-11-05 | 2006-05-11 | Grant Heinicke | Propranolol formulations |
US20060099258A1 (en) | 2004-11-05 | 2006-05-11 | Grant Heinicke | Propranolol formulations |
US20060110327A1 (en) | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
ATE405952T1 (en) | 2005-02-17 | 2008-09-15 | Europ High Temperature Superco | METHOD FOR PRODUCING BIAXIALLY ORIENTED THIN LAYERS |
US20060204575A1 (en) | 2005-03-11 | 2006-09-14 | Hengsheng Feng | Amphetamine formulations |
EP1898891A2 (en) | 2005-05-13 | 2008-03-19 | Alza Corporation | Multilayer drug delivery system with barrier against antagonist exposure |
WO2006130471A1 (en) | 2005-05-27 | 2006-12-07 | The Regents Of The University Of California | The use delta opioid receptor agonists and/or inverse agonists to inhibit the consumption of substances of abuse |
US20070020339A1 (en) * | 2005-07-20 | 2007-01-25 | Pharmorx Inc. | Compositions and methods for controlling abuse of medications |
US8329744B2 (en) | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
WO2007080509A2 (en) * | 2006-01-12 | 2007-07-19 | Wockhardt Ltd | Sustained release compositions of alfuzosin |
US20070185145A1 (en) | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
US20070243250A1 (en) | 2006-04-17 | 2007-10-18 | Actavis Group Ptc Hf | Oral Dosage Formulations and Methods of Preparing the Same |
US20070243245A1 (en) | 2006-04-17 | 2007-10-18 | Actavis Group Ptc Hf | Oral Dosage Formulations, Methods of Preparing the Same, and Methods of Reducing Food Effects on Drug Release |
PL2526932T3 (en) | 2006-06-19 | 2017-12-29 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
WO2008011596A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
JP2010506833A (en) | 2006-10-11 | 2010-03-04 | アルファーマ,インコーポレイテッド | Pharmaceutical composition |
US20080318994A1 (en) | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment |
US20080318993A1 (en) | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment |
WO2009032270A2 (en) | 2007-09-04 | 2009-03-12 | Alpharma, Inc. | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
AU2008346870A1 (en) | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20100151014A1 (en) | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
-
2007
- 2007-06-19 PL PL12163626T patent/PL2526932T3/en unknown
- 2007-06-19 CN CN2007800303040A patent/CN101677963B/en not_active Expired - Fee Related
- 2007-06-19 DK DK12163626.0T patent/DK2526932T3/en active
- 2007-06-19 ES ES12153443.2T patent/ES2622576T3/en active Active
- 2007-06-19 DK DK13154883.6T patent/DK2719378T3/en active
- 2007-06-19 HU HUE12163626A patent/HUE033058T2/en unknown
- 2007-06-19 HU HUE12153443A patent/HUE032156T2/en unknown
- 2007-06-19 PT PT121636260T patent/PT2526932T/en unknown
- 2007-06-19 SI SI200731914A patent/SI2484346T1/en unknown
- 2007-06-19 RU RU2009101082/15A patent/RU2445077C2/en not_active IP Right Cessation
- 2007-06-19 PT PT07809672T patent/PT2034975E/en unknown
- 2007-06-19 SI SI200730929T patent/SI2034975T1/en unknown
- 2007-06-19 EP EP12153443.2A patent/EP2484346B1/en not_active Not-in-force
- 2007-06-19 WO PCT/US2007/014282 patent/WO2007149438A2/en active Application Filing
- 2007-06-19 KR KR1020097000449A patent/KR101486228B1/en active IP Right Grant
- 2007-06-19 KR KR20157004494A patent/KR20150029762A/en not_active Application Discontinuation
- 2007-06-19 ES ES07809672T patent/ES2385612T3/en active Active
- 2007-06-19 PL PL13154883T patent/PL2719378T3/en unknown
- 2007-06-19 KR KR1020147011462A patent/KR20140079441A/en not_active Application Discontinuation
- 2007-06-19 EP EP13154883.6A patent/EP2719378B1/en not_active Not-in-force
- 2007-06-19 DK DK12153443.2T patent/DK2484346T3/en active
- 2007-06-19 PL PL12153443T patent/PL2484346T3/en unknown
- 2007-06-19 JP JP2009516543A patent/JP5566102B2/en not_active Expired - Fee Related
- 2007-06-19 AT AT07809672T patent/ATE552829T1/en active
- 2007-06-19 BR BRPI0714039A patent/BRPI0714039A8/en not_active IP Right Cessation
- 2007-06-19 AU AU2007261451A patent/AU2007261451A1/en not_active Abandoned
- 2007-06-19 SI SI200731942A patent/SI2526932T1/en unknown
- 2007-06-19 NZ NZ573757A patent/NZ573757A/en not_active IP Right Cessation
- 2007-06-19 HU HUE13154883A patent/HUE031590T2/en unknown
- 2007-06-19 MX MX2008016372A patent/MX2008016372A/en active IP Right Grant
- 2007-06-19 US US11/820,499 patent/US8158156B2/en active Active
- 2007-06-19 DK DK07809672.4T patent/DK2034975T3/en active
- 2007-06-19 SI SI200731832A patent/SI2719378T1/en unknown
- 2007-06-19 PT PT121534432T patent/PT2484346T/en unknown
- 2007-06-19 EP EP12163626.0A patent/EP2526932B1/en not_active Not-in-force
- 2007-06-19 CA CA2655835A patent/CA2655835C/en not_active Expired - Fee Related
- 2007-06-19 PT PT131548836T patent/PT2719378T/en unknown
- 2007-06-19 ES ES12163626.0T patent/ES2636657T3/en active Active
- 2007-06-19 PL PL07809672T patent/PL2034975T3/en unknown
- 2007-06-19 EP EP07809672A patent/EP2034975B8/en not_active Not-in-force
- 2007-06-19 ES ES13154883.6T patent/ES2600141T3/en active Active
-
2008
- 2008-12-10 IL IL195834A patent/IL195834A/en active IP Right Grant
- 2008-12-11 ZA ZA2008/10501A patent/ZA200810501B/en unknown
-
2009
- 2009-03-06 US US12/399,923 patent/US7682634B2/en not_active Expired - Fee Related
- 2009-03-06 US US12/399,918 patent/US7682633B2/en not_active Expired - Fee Related
-
2010
- 2010-02-22 US US12/710,016 patent/US8877247B2/en not_active Expired - Fee Related
-
2012
- 2012-02-13 US US13/371,760 patent/US8846104B2/en not_active Expired - Fee Related
- 2012-03-23 US US13/427,986 patent/US20120189705A1/en not_active Abandoned
- 2012-06-13 CY CY20121100539T patent/CY1112868T1/en unknown
-
2013
- 2013-02-01 HK HK13101423.0A patent/HK1173980A1/en not_active IP Right Cessation
- 2013-11-15 AU AU2013257508A patent/AU2013257508B2/en not_active Ceased
-
2014
- 2014-10-01 US US14/503,781 patent/US20150024058A1/en not_active Abandoned
- 2014-10-19 IL IL235150A patent/IL235150A/en active IP Right Grant
-
2016
- 2016-05-03 US US15/145,717 patent/US20170056329A1/en not_active Abandoned
- 2016-10-04 AU AU2016238844A patent/AU2016238844A1/en not_active Abandoned
- 2016-10-10 CY CY20161100999T patent/CY1118077T1/en unknown
-
2017
- 2017-03-22 CY CY20171100365T patent/CY1118982T1/en unknown
- 2017-07-24 CY CY20171100789T patent/CY1119334T1/en unknown
-
2018
- 2018-01-22 US US15/876,589 patent/US20190314289A1/en not_active Abandoned
- 2018-03-16 AU AU2018201915A patent/AU2018201915A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0271193A2 (en) * | 1986-10-31 | 1988-06-15 | Euroceltique S.A. | Controlled release hydromorphone composition |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US20030004177A1 (en) * | 2001-05-11 | 2003-01-02 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030124185A1 (en) * | 2001-08-06 | 2003-07-03 | Benjamin Oshlack | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20040254208A1 (en) * | 2003-04-29 | 2004-12-16 | Eckard Weber | Compositions for affecting weight loss |
WO2005055981A2 (en) * | 2003-12-09 | 2005-06-23 | Euro-Celtique S.A. | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
WO2005081825A2 (en) * | 2004-02-23 | 2005-09-09 | Euro-Celtique S.A. | Abuse resistance opioid transdermal delivery device |
WO2007145863A2 (en) * | 2006-06-05 | 2007-12-21 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007149438A3 (en) | Pharmaceutical compositions | |
WO2009032270A3 (en) | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer | |
WO2007109605A3 (en) | Pharmaceutical compositions | |
WO2008037421A3 (en) | Pharmaceutical compositions comprising an s1p modulator | |
AU2013257508A1 (en) | Pharmaceutical compositions | |
EP1991497B8 (en) | Method for depositing high aspect ratio molecular structures | |
WO2007134279A3 (en) | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
WO2008049116A3 (en) | Substituted indoles | |
WO2008051942A3 (en) | Farnesoid x receptor agonists | |
EP1740156B8 (en) | Method for the production of an abuse-proof, solid form of administration | |
WO2006121941A3 (en) | Pharmaceutical compositions comprising imatinib and a release retardant | |
IL197933A (en) | Kinase inhibitors, pharmaceutical compositions comprising such compounds and uses thereof | |
WO2009082701A8 (en) | Hcv protease inhibitors and uses thereof | |
WO2007050802A3 (en) | Novel opioid antagonists | |
AU2006311709A8 (en) | Service interfacing for telephony | |
IL196426A0 (en) | Microparticulates based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same | |
WO2008140553A3 (en) | Mapk/erk kinase inhibitors | |
WO2008051564A3 (en) | Crystalline forms of palonosetron hydrochloride | |
WO2007133921A3 (en) | Systems and methods for determining a packing fraction of a substance | |
WO2007148102A3 (en) | Crystalline duloxetine hydrochloride | |
WO2008070354A3 (en) | 5- and 6- substituted benzimidazole thiophene compounds | |
WO2007117961A3 (en) | Renin inhibitors | |
WO2008028885A3 (en) | Composition comprising an angiotensin ii receptor antagonist | |
WO2006119779A3 (en) | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution | |
WO2007110068A3 (en) | Novel isooxazole derivatives and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780030304.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07809672 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007809672 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 195834 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2655835 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009516543 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007261451 Country of ref document: AU Ref document number: 573757 Country of ref document: NZ Ref document number: MX/A/2008/016372 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097000449 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 288/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009101082 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007261451 Country of ref document: AU Date of ref document: 20070619 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0714039 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081218 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020157004494 Country of ref document: KR |